FTC expert says drugmakers’ settlement evolved too fast
The Federal Trade Commission’s expert witness said on Tuesday that a 2010 co-promotional agreement between Impax and rival drugmaker Endo was highly unusual because the agreement to pay Impax $10 million to develop a Parkinson’s drug occurred after only one month of negotiations.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10